{"id":905776,"date":"2025-11-05T06:17:45","date_gmt":"2025-11-05T11:17:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/"},"modified":"2025-11-05T06:17:45","modified_gmt":"2025-11-05T11:17:45","slug":"telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/","title":{"rendered":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and INDIANAPOLIS, Nov.  05, 2025  (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK).<\/p>\n<p align=\"justify\">Kevin Richardson, Chief Executive Officer, Precision Medicine will take part in a fireside chat with UBS on Monday, November 10, 2025 at 12.30pm EST (Tuesday, Nov 11 at 4:30am AEDT).<\/p>\n<p align=\"justify\">Richard Valeix, Chief Executive Officer, Therapeutics will take part in a fireside chat with Jefferies on Tuesday, November 18, 2025 at 10am GMT (9pm AEDT).<\/p>\n<p align=\"justify\">Each session will be webcast live, and accessible through Telix\u2019s Investor Relations website.<\/p>\n<p align=\"justify\">For more information including how to register, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O2BuX33bvNC37EHEl14E6E9fFvZtz-zcSNawVlkvNaI9_JkHVgxb9BXwfyTMxyyTm98r3jeBzRyIuLd2uLpkbYVubEaT_xmC7hbbbfjn1Lp86PLmlV2UJDZENTEPl6l84LMWYfH-UD6LomOztSCKbCKANN216DGoOQ59Zyntn_c=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.telixpharma.com\/events-presentations<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Telix Pharmaceuticals Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).<\/p>\n<p align=\"justify\">Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u0mGKS2HajmFW2qSEUBHGTxxZy7wDUXK4YFacbXlBCjLz2te5hH361QVx6zuSFrw6uHzp543JdynqlfNgHazQoKdyXMrv9uT8Jhq7aKs4bk=\" rel=\"nofollow\" target=\"_blank\">www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NrpXmUpNwgurAgb8YaziyQiaIgpQTkWW-Ceo6op-T3zjSCxLNvZf_9C8I1HSoYzoz6ODXSV0T7nc8tATWwME0_IgFLeBXND7Ki2MYRplxcE=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h3CqFT2MG8di8Hgde9TB4qLuJhkD8Ro9gqsuxKEYqOfVxTTAjATKdcglsE0Y28h9YJbmwCCRX3bXkus7TSBnng==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xPPOR1tsR8IfvSGQJ4gV6X_jRj4MjCmBVJdcPMu2TfU6sPLhVgGN6BHiWiwCufVn-vfQALMwNbWoizg14rcaEV1095EbKvMGicxuoAlC138=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a><\/p>\n<p align=\"justify\">\n        <strong>Telix Investor Relations (Global)<\/strong>\n      <\/p>\n<p align=\"justify\">Ms. Kyahn Williamson<br \/>Telix Pharmaceuticals Limited<br \/>SVP Investor Relations and Corporate Communications<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Auj5tMaNFjk4XodJRpZLMSNpo7lVOMvqYeV976tbx-Zr55ru43Qpr5w2zViazYqifEKHmVj-DJdzeQ1icA45chaJI9WqGVGQloZoLHIN9564biFk8KN6Mb-wWsHC3qtPWiQF43lhJa4lmWRbatVEyQ==\" rel=\"nofollow\" target=\"_blank\">kyahn.williamson@telixpharma.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Telix Investor Relations (U.S.)\u202f\u00a0<\/strong>\n      <\/p>\n<p>Annie Kasparian\u202f\u00a0<br \/>Telix Pharmaceuticals Limited\u202f\u00a0<br \/>Director Investor Relations and Corporate Communications\u202f\u00a0<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WRIKbxQ1FBlhhqyp-oO2dCwQD4Pj9tHyFnjH5oYCfFVU1zBUhYXT8jt6cGQTU7pkaCSFPyDOvkxoCJrbBEXpVqKWBbewpef8OidjIyBnksG8sAwmYMtFMmgJOT56VAyKyiXkrgdl0v9iNZiUGGgJdg==\" rel=\"nofollow\" target=\"_blank\">annie.kasparian@telixpharma.com<\/a><\/p>\n<p align=\"center\">Legal Notices<\/p>\n<p align=\"center\">\n        <em>Cautionary Statement Regarding Forward-Looking Statements.\u00a0 <\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <em>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. \u202fTo the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as \u201cmay\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201coutlook\u201d, \u201cforecast\u201d and \u201cguidance\u201d, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix\u2019s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix\u2019s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix\u2019s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix\u2019s preclinical and clinical trials, and Telix\u2019s research and development programs; Telix\u2019s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix\u2019s product candidates, manufacturing activities and product marketing activities; Telix\u2019s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix\u2019s product candidates, if or when they have been approved; Telix\u2019s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix\u2019s expenses, future revenues and capital requirements; Telix\u2019s financial performance; developments relating to Telix\u2019s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix\u2019s business; and the pricing and reimbursement of Telix\u2019s product candidates, if and after they have been approved. Telix\u2019s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>\u00a92025 Telix Pharmaceuticals Limited. All rights reserved.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmQ4NWYxZGItMzhhMy00ZTA5LWI0YmYtODMyM2VkMWVhYjJkLTEwOTQ4MTMtMjAyNS0xMS0wNS1lbg==\/tiny\/Telix-Pharmaceuticals-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK). Kevin Richardson, Chief Executive Officer, Precision Medicine will take part in a fireside chat with UBS on Monday, November 10, 2025 at 12.30pm EST (Tuesday, Nov 11 at 4:30am AEDT). Richard Valeix, Chief Executive Officer, Therapeutics will take part in a fireside chat with Jefferies on Tuesday, November 18, 2025 at 10am GMT (9pm AEDT). Each session will be webcast live, and accessible through Telix\u2019s Investor Relations website. For more information including how to register, please visit: https:\/\/ir.telixpharma.com\/events-presentations\u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Telix to Participate in UBS and Jefferies Global Healthcare Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-905776","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Telix to Participate in UBS and Jefferies Global Healthcare Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix to Participate in UBS and Jefferies Global Healthcare Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK). Kevin Richardson, Chief Executive Officer, Precision Medicine will take part in a fireside chat with UBS on Monday, November 10, 2025 at 12.30pm EST (Tuesday, Nov 11 at 4:30am AEDT). Richard Valeix, Chief Executive Officer, Therapeutics will take part in a fireside chat with Jefferies on Tuesday, November 18, 2025 at 10am GMT (9pm AEDT). Each session will be webcast live, and accessible through Telix\u2019s Investor Relations website. For more information including how to register, please visit: https:\/\/ir.telixpharma.com\/events-presentations\u00a0 &hellip; Continue reading &quot;Telix to Participate in UBS and Jefferies Global Healthcare Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T11:17:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telix to Participate in UBS and Jefferies Global Healthcare Conferences\",\"datePublished\":\"2025-11-05T11:17:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/\"},\"wordCount\":969,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/\",\"name\":\"Telix to Participate in UBS and Jefferies Global Healthcare Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=\",\"datePublished\":\"2025-11-05T11:17:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix to Participate in UBS and Jefferies Global Healthcare Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences - Market Newsdesk","og_description":"MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK). Kevin Richardson, Chief Executive Officer, Precision Medicine will take part in a fireside chat with UBS on Monday, November 10, 2025 at 12.30pm EST (Tuesday, Nov 11 at 4:30am AEDT). Richard Valeix, Chief Executive Officer, Therapeutics will take part in a fireside chat with Jefferies on Tuesday, November 18, 2025 at 10am GMT (9pm AEDT). Each session will be webcast live, and accessible through Telix\u2019s Investor Relations website. For more information including how to register, please visit: https:\/\/ir.telixpharma.com\/events-presentations\u00a0 &hellip; Continue reading \"Telix to Participate in UBS and Jefferies Global Healthcare Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-05T11:17:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences","datePublished":"2025-11-05T11:17:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/"},"wordCount":969,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/","name":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=","datePublished":"2025-11-05T11:17:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTE2NiM3MjQ1NDE4IzIwODMyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-to-participate-in-ubs-and-jefferies-global-healthcare-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=905776"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905776\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=905776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=905776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=905776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}